EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
出版年份 2021 全文链接
标题
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
作者
关键词
fibrosis, steatosis, farnesoid X receptor, clinical trial, alanine aminotransferase, proton density fat fraction
出版物
JOURNAL OF HEPATOLOGY
Volume 76, Issue 3, Pages 506-517
出版商
Elsevier BV
发表日期
2021-11-03
DOI
10.1016/j.jhep.2021.10.018
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis
- (2021) Andrea Dennis et al. Frontiers in Endocrinology
- FXR agonists for NASH: How are they different and what difference do they make?
- (2021) Claus Kremoser JOURNAL OF HEPATOLOGY
- NAFLD 2020: The State of the Disease
- (2020) Thomas G. Cotter et al. GASTROENTEROLOGY
- Multicenter validation of association between decline in MRI‐PDFF and histologic response in nonalcoholic steatohepatitis
- (2020) Rohit Loomba et al. HEPATOLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
- (2020) Ping An et al. LIVER INTERNATIONAL
- Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
- (2020) Stephen A. Harrison et al. GASTROENTEROLOGY
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction
- (2019) Shen Li et al. FASEB JOURNAL
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis
- (2019) Fernando Bril et al. JOURNAL OF HEPATOLOGY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
- (2019) Marcos Pedrosa et al. Contemporary Clinical Trials
- Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
- (2019) Mohammad Shadab Siddiqui et al. JOURNAL OF HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects
- (2018) A. Ahmad et al. JOURNAL OF HEPATOLOGY
- A critical review of endpoints for non-cirrhotic NASH therapeutic trials
- (2018) Vlad Ratziu JOURNAL OF HEPATOLOGY
- FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver
- (2018) Romeo Papazyan et al. JOURNAL OF LIPID RESEARCH
- Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
- (2018) Rohit Loomba et al. GASTROENTEROLOGY
- Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis
- (2018) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib
- (2018) Saumya Jayakumar et al. JOURNAL OF HEPATOLOGY
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Elevated gamma-glutamyl transferase is associated with subclinical inflammation independent of cardiometabolic risk factors in an asymptomatic population: a cross-sectional study
- (2016) Shozab S. Ali et al. Nutrition & Metabolism
- FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
- (2016) Len Verbeke et al. Scientific Reports
- Diagnostic Performance of Magnetic Resonance Elastography in Staging Liver Fibrosis: A Systematic Review and Meta-analysis of Individual Participant Data
- (2015) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Endogenous production of reactive oxygen species by the NADPH oxidase complexes is a determinant of γ-glutamyltransferase expression
- (2011) Chandra Ravuri et al. FREE RADICAL RESEARCH
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elevated Serum Alanine Aminotransferase and γ-Glutamyltransferase and Mortality in the United States Population
- (2008) Constance E. Ruhl et al. GASTROENTEROLOGY
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
- (2008) Yan-Dong Wang et al. HEPATOLOGY
- Targeting bile-acid signalling for metabolic diseases
- (2008) Charles Thomas et al. NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now